TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Americans Still Worry About Cost Obama's ability to sell his health overhaul relies heavily on convincing small business owners and other ordinary citizens who are worried about the cost of insuring every American. online.barrons.com |
Why I'm Taking a Foothold in Generex Now VFC submits: In response to a number of requests that I've received via email or comments asking for 'VFC's Take' on numerous stocks that readers have found, I'll do my best to address as many as I can, as long as everyone takes a few things into account while reading: - I have not thoroughly researched all of the stocks that I'm about to comment on. I've done the initial DD but my opinions are mostly based on my first impressions of the stock. I'm merely providing VFC's Take, as requested. Use that as a starting point to do your own DD.Complete Story » seekingalpha.com |
GOP Targets AARP Insurance Ties Republicans are taking aim at AARP's financial ties to the insurance industry as the advocacy group take a prominent role in support of health-care bill. online.barrons.com |
Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations (PR Newswire) Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer. us.rd.yahoo.com |
GenVec's Hearing Loss Program Gets Welcome Boost from Novartis The Burrill Report submits: GenVec's (GNTX) pre-clinical treatment for hearing loss and balance disorders has new support from Novartis' (NVS) deep pockets, following the consummation of a deal worth up to $213.6 million for the Gaithersburg, Maryland biopharmaceutical company. The agreement, part of a steady licensing-driven pipeline expansion for Novartis, gives the Swiss pharmaceutical global rights to GenVec's hearing loss and balance disorders program, which has shown potential in the restoration of hearing and balance loss in certain cases where no treatment currently exists.Hearing loss is divided into two main categories: conductive hearing loss, due to mechanical problems in the outer or middle ear and sensorineural hearing loss, due to inner ear problems. While conductive hearing loss is often reversible, sensorineural hearing loss does not have a known or approved treatment. GenVec estimates that the market for hearing loss treatments alone might represent an opportunity of at least $6 billion. Novartis will acquire $2 million of GenVec stock as part of the deal. In addition, GenVec will receive further funding from Novartis for a second research program targeting hearing loss. GenVec is eligible to receive up to $213.6 million altogether, including upfront and milestone payments, in addition to royalties on future sales. GenVec's CEO, Paul Fischer says the collaboration with Novartis “provides an excellent mechanism to move the development of new treatments forward.” The deal, officially inked between GenVec and the Novartis Institutes for BioMedical Research on January 13, provides GenVec a welcome turn of fortune, considering the company flirted with being delisted from the Nasdaq in September 2009 after the minimum bid price of its common stock fell below $1.00 per share for 30 consecutive business days. The company regained compliance in January. GenVec's leading drug candidate, TNFerade, is currently in a pivotal late-stage study of its effectiveness in treating locally advanced pancreatic cancer. TNFerade is also being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. Complete Story » seekingalpha.com |